{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:22:39Z","timestamp":1784258559287,"version":"3.55.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1093\/jac\/dky030","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T23:13:06Z","timestamp":1516317186000},"page":"1651-1658","source":"Crossref","is-referenced-by-count":11,"title":["Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study"],"prefix":"10.1093","volume":"73","author":[{"given":"Sharat","family":"Chandra","sequence":"first","affiliation":[{"name":"Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA"},{"name":"Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M","family":"Davies","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Teusink-Cross","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rich","family":"Tarin","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A","family":"Marsh","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A","family":"Vinks","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA"},{"name":"Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinda A","family":"Mehta","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,2,21]]},"reference":[{"key":"key\n\t\t\t\t20180518035553_dky030-B1","first-page":"519","article-title":"Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients","volume":"139","author":"Barnes","year":"2007","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t20180518035553_dky030-B2","first-page":"1143","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20180518035553_dky030-B3","first-page":"393","article-title":"Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients","volume":"61","author":"Science","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"key\n\t\t\t\t20180518035553_dky030-B4","first-page":"531","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035553_dky030-B5","first-page":"1210","article-title":"Aspergillosis in children with cancer: a 34-year experience","volume":"29","author":"Abbasi","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035553_dky030-B6","first-page":"852","article-title":"Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000","volume":"40","author":"Pfaller","year":"2002","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180518035553_dky030-B7","first-page":"250","article-title":"Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell\u2019 Adulto","volume":"28","author":"Menichetti","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035553_dky030-B8","first-page":"803","article-title":"Safety and interactions of new antifungals in stem cell transplant recipients","volume":"11","author":"Girmenia","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"key\n\t\t\t\t20180518035553_dky030-B9","first-page":"219","article-title":"Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus","volume":"55","author":"Hatano","year":"2002","journal-title":"J Antibiot (Tokyo)"},{"key":"key\n\t\t\t\t20180518035553_dky030-B10","first-page":"614","article-title":"Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis","volume":"44","author":"Ikeda","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B11","first-page":"485","article-title":"In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide","volume":"46","author":"Mikamo","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B12","first-page":"57","article-title":"In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi","volume":"44","author":"Tawara","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B13","first-page":"1857","article-title":"Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits","volume":"46","author":"Petraitis","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B14","first-page":"e45","article-title":"Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation","volume":"37","author":"Albano","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"key\n\t\t\t\t20180518035553_dky030-B15","first-page":"639","article-title":"Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg\/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"42","author":"Yoshikawa","year":"2014","journal-title":"Infection"},{"key":"key\n\t\t\t\t20180518035553_dky030-B16","first-page":"630","article-title":"Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia","volume":"31","author":"Undre","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"key\n\t\t\t\t20180518035553_dky030-B17","first-page":"1458","article-title":"Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study","volume":"16","author":"Mehta","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"key\n\t\t\t\t20180518035553_dky030-B18","first-page":"3317","article-title":"Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients","volume":"49","author":"Seibel","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B19","first-page":"1407","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035553_dky030-B20","first-page":"S652","article-title":"Safety and efficacy of intermittent intravenous administration of high-dose micafungin","volume":"61","author":"Neofytos","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180518035553_dky030-B21","first-page":"2633","article-title":"Population pharmacokinetics of micafungin in neonates and young infants","volume":"54","author":"Hope","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B22","first-page":"3714","article-title":"Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing","volume":"51","author":"Hope","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B23","first-page":"83","article-title":"Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children\u2019s oncology group","volume":"70","author":"Edwards","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t20180518035553_dky030-B24","first-page":"271","article-title":"Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients","volume":"11","author":"Carter","year":"2009","journal-title":"Paediatr Drugs"},{"key":"key\n\t\t\t\t20180518035553_dky030-B25","first-page":"3323","article-title":"In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180518035553_dky030-B26","first-page":"2640","article-title":"Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp","volume":"47","author":"Arikan","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B27","first-page":"4559","article-title":"Antifungal activity of micafungin in serum","volume":"53","author":"Ishikawa","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B28","first-page":"1601","article-title":"Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies","volume":"52","author":"Wang","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180518035553_dky030-B29","author":"Beal","year":"2009"},{"key":"key\n\t\t\t\t20180518035553_dky030-B30","first-page":"e50.","article-title":"Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"key\n\t\t\t\t20180518035553_dky030-B31","first-page":"303","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"key\n\t\t\t\t20180518035553_dky030-B32","first-page":"51","article-title":"Xpose\u2013an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM","volume":"58","author":"Jonsson","year":"1999","journal-title":"Comput Methods Programs Biomed"},{"key":"key\n\t\t\t\t20180518035553_dky030-B33","first-page":"968","article-title":"Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B34","first-page":"3846","article-title":"In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies","volume":"46","author":"Ernst","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B35","first-page":"1527","article-title":"Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease","volume":"70","author":"Bochennek","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B36","first-page":"1145","article-title":"Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction","volume":"45","author":"Hebert","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180518035553_dky030-B37","first-page":"905","article-title":"Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents","volume":"59","author":"Hope","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035553_dky030-B38","first-page":"S59","article-title":"Allometric size: the scientific theory and extension to normal fat mass","volume":"109S","author":"Holford","year":"2017","journal-title":"Eur J Pharm Sci"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/6\/1651\/24804697\/dky030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T03:56:06Z","timestamp":1526615766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/6\/1651\/4898170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,21]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,2,21]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky030","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2018,2,21]]}}}